A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

NCT05364944 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Stopped The recruitment was halted for strategic reasons

Conditions

Acromegaly
GEP-NET

Interventions

DRUG: Debio 4126
DRUG: Sandostatin LAR
DRUG: Somatuline ATG

Sponsor

Debiopharm International SA